Entrada Therapeutics says safety panel recommends 15 mg/kg dose for next cohort in Duchenne trial
TRDA•An independent safety committee recommended advancing Entrada Therapeutics’ ELEVATE-45-201 trial to a third cohort at 15 mg/kg. Results from the fully enrolled second cohort of eight participants are expected in the first half of 2027.




